


Quadria Capital closes \$1 B Fund III to advance healthcare transformation across Asia

27 May 2025 | News

Strategic partnership with Gulf capital positions fund to capitalise on Asia's \$5 trillion healthcare opportunity



Quadria Capital, Asia's premier healthcare-focused private equity firm, has announced the final close of its Fund III with \$1.07 billion in total commitments, significantly exceeding its original \$800 million target with strong backing from Gulf Cooperation Council (GCC) investors.

The oversubscribed fundraise comprises over \$954 million in primary commitments and \$114 million in committed coinvestment capital. An additional \$300 million co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately \$1.3 billion upon full deployment.

This latest fundraise is around 60% larger than the firm's previous \$600 million fund raised in 2020, cementing Quadria's position as one of the largest dedicated healthcare private equity funds in Asia.

Fund III will build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes, with targeted co-investment opportunities for Gulf Limited Partners seeking direct exposure to Asia's highest-growth healthcare assets.

Already nearly 40% deployed—including closed and signed investments—the fund has invested in Aragen Life Sciences (a global CRDMO serving over 400 pharmaceutical clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's

leading eye o	care chain). co-investmen	Two new inve t opportunities	estments in	Southeast	Asia a	are e	xpected	soon,	with	Gulf	investors	positioned	to